Aurobindo Pharma Limited

NSE: AUROPHARMA

Healthcare Healthcare

₹1,621.4

-2.73%EOD · 19 Oct

Aurobindo Pharma Limited is a listed Healthcare company on NSE/BSE. Detailed profile data is being compiled — check BSE filings for the latest disclosures.

Market Cap

₹93,292 Cr

52W Range

₹1740 / ₹1080

Volume

736K

52.3% delivery

1Y Return

+46.2%

P/E Ratio

26.1

P/B Ratio

2.6

ROE

9.9%

Debt / Equity

21.31

Peers in Healthcare

Top 8 by market cap

Company	LTP	Market Cap	P/E	P/B	ROE %	Div Yld %
Aurobindo Pharma Limited(this stock)	₹1,621.4	₹93,292 Cr	26.1	2.6	9.9%	0.00%
Divi's Laboratories LimitedDIVISLAB	₹9,087	₹2.41 L Cr	83.0	14.5	16.2%	0.33%
Torrent Pharmaceuticals LimitedTORNTPHARM	₹4,558.7	₹1.73 L Cr	72.8	18.4	17.0%	0.83%
Laurus Labs LimitedLAURUSLABS	₹2,069	₹1.12 L Cr	101.8	21.0	17.7%	0.12%
Zydus Lifesciences LimitedZYDUSLIFE	₹1,113.9	₹1.11 L Cr	25.0	4.2	18.3%	0.09%
Apollo Hospitals Enterprise LimitedAPOLLOHOSP	₹7,700	₹1.11 L Cr	54.3	12.0	21.5%	0.25%
Mankind Pharma LimitedMANKIND	₹2,253.2	₹93,067 Cr	46.0	5.8	12.4%	0.00%
Max Healthcare Institute LimitedMAXHEALTH	₹830	₹80,785 Cr	56.7	7.7	14.3%	0.23%
Glenmark Pharmaceuticals LimitedGLENMARK	₹2,210.2	₹62,377 Cr	35.0	6.0	14.1%	0.11%

Quality Score

Durability · Valuation · Momentum — objective math, not advice

60/100

Composite score: 40% quality, 30% valuation, 30% momentum

QualityWeak · 35

ValuationGood · 58

MomentumStrong · 95

High debt load (D/E 21.3)

In confirmed uptrend (Stage 2)

Technical Indicators

Full analysis · objective math, not advice

Returns

-2.7%

-5.0%

-6.5%

+5.7%

+14.1%

+46.2%

Weinstein Stage

Stage 2 — Advancing (uptrend)

RSI (14)

36 Neutral

Trend Template

6/7strong

RS vs Nifty (3M)

+10.9pp

Moving Averages (price vs MA)

20-DMA

₹1684

below

50-DMA

₹1668

below

150-DMA

₹1533

above

200-DMA

₹1447

above

From 52W High

-6.8%

From 52W Low

+50.1%

Support (20D)

₹1616

Resistance (20D)

₹1740

Technical indicators are objective calculations from historical EOD prices (RSI, moving averages, Weinstein stage, Minervini trend-template, relative strength). For educational reference only — not a buy/sell recommendation.

Quality Signals

Multi-year consistency · Source: Screener annual data

ROE Consistency

0/0 years ≥15%

Revenue Growth

+3.0% CAGR

Up 9 of last 11 years

Earnings Quality

Fully cash-backed

OCF / Net Profit = 1.21x · 12/12 yrs +ve cash flow

Quality signals derived from multi-year annual financials. ROE consistency = years with ≥15% return on equity. Cash-backed = operating cash flow vs reported net profit (≥1x means earnings are converted to real cash, not just accruals). Educational reference only — not investment advice.

News & FilingsGoogle News + BSE

News via Google News · Not verified by IPOpulse · Not investment advice

Community discussion(0)

No comments yet — be the first to share your view.